

Journal of Hepatology 38 (2003) 179-187

Journal of Hepatology

www.elsevier.com/locate/jhep

## Selective blockade of mGlu5 metabotropic glutamate receptors is protective against acetaminophen hepatotoxicity in mice

Marianna Storto<sup>1</sup>, Richard Teke Ngomba<sup>1</sup>, Giuseppe Battaglia<sup>1</sup>, Isabel Freitas<sup>2</sup>, Patrizia Griffini<sup>2</sup>, Plinio Richelmi<sup>3</sup>, Ferdinando Nicoletti<sup>1,4,\*</sup>, Mariapia Vairetti<sup>5</sup>

<sup>1</sup>I.N.M. Neuromed, Loc. Camerelle, 86077 Pozzilli (Isernia), Italy
 <sup>2</sup>Department of Animal Biology, University of Pavia, Pavia, Italy
 <sup>3</sup>University of Insubria Medical School, Varese, Italy
 <sup>4</sup>Department of Human Physiology and Pharmacology, University 'La Sapienza', Rome, Italy
 <sup>5</sup>Department of Internal Medicine and Medical Therapy, University of Pavia, Pavia, Italy

*Background/Aims*: mGlu5 metabotropic glutamate receptor antagonists protect rat hepatocytes against hypoxic death. Here, we have examined whether mGlu5 receptor antagonists are protective against liver damage induced by oxidative stress.

*Methods*: Toxicity of isolated hepatocytes was induced by *tert*-butylhydroperoxide (t-BuOOH) after pretreatment with the mGlu5 receptor antagonists, MPEP, SIB-1757 and SIB-1893. The effect of these drugs was also examined in mice challenged with toxic doses of acetaminophen.

*Results*: Addition of tBuOOH (0.5 mM) to isolated hepatocytes induced cell death ( $70 \pm 5\%$  at 3 h). Addition of MPEP or SIB-1893 to hepatocytes reduced both the production of reactive oxygen species (ROS) and cell toxicity induced by t-BuOOH (tBuOOH =  $70 \pm 5\%$ ; tBuOOH + MPEP =  $57 \pm 6\%$ ; tBuOOH + SIB-1893 =  $40 \pm 4\%$ ). In mice, a single injection of acetaminophen (300 mg/kg, i.p.) induced centrilobular liver necrosis, which was detectable after 24 h. MPEP (20 mg/kg, i.p.) substantially reduced liver necrosis and the production of ROS, although it did not affect the conversion of acetaminophen into the toxic metabolite, *N*-acetylbenzoquinoneimine. MPEP, SIB-1893 and SIB-1757 (all at 20 mg/kg, i.p.) also reduced the increased expression and activity of liver iNOS induced by acetaminophen.

*Conclusions*: We conclude that pharmacological blockade of mGlu5 receptors might represent a novel target for the treatment of drug-induced liver damage.

© 2002 European Association for the Sudy of the Liver. Published by Elsevier Science B.V. All rights reserved.

Keywords: Liver; Hepatotoxicity; Cell damage; Oxidative stress; Acetaminophen; mGlu5 receptor antagonist

### 1. Introduction

Glutamate (Glu) receptors are present not only in the central nervous system (CNS) but also in peripheral organs, and even in cells that do not originate from the neural crest [2–5]. Glu receptors either form membrane cation channels ('ionotropic' receptors) or couple to G proteins ('metabo-tropic' or mGlu receptors). mGlu receptors are members of class-3 G-protein coupled receptors and form a family of

eight subtypes subdivided into three groups on the basis of their sequence homology, pharmacological profile and transduction mechanisms [6]. Group-I receptors (subtypes mGlu1 and -5) are coupled to polyphosphoinositide hydrolysis, whereas group-II and -III receptors (subtypes mGlu2 and -3 and mGlu4, -6, -7 and -8, respectively) are negatively coupled to adenylyl cyclase [6]. The study of peripheral mGlu receptors moved from the observation that mGlu4 receptors are present in taste buds, and contribute to the process of taste discrimination [4]. We have recently shown that hepatocytes express functional mGlu5 receptors coupled to polyphosphoinositide hydrolysis [1,7]. The presence of micromolar concentrations of glutamate in the portal blood, as well as in the extracellular fluid of isolated

Received 21 February 2002; received in revised form 17 October 2002; accepted 29 October 2002

<sup>\*</sup> Corresponding author. Tel.: +39-0865-915233; fax: +39-0865-927575.

E-mail address: nicoletti@neuromed.it (F. Nicoletti).

hepatocytes [1] suggests that mGlu5 receptors are endogenously activated and may therefore be involved in several aspects of liver physiology and pathology. Because mGlu5 receptors contribute to excitotoxic neuronal damage [8], we have initially examined whether mGlu5 receptor agonists or antagonists influence cell damage in isolated hepatocytes subjected to hypoxia. While receptor agonists accelerate cell death, receptor blockade with MPEP (a selective, potent and non-competitive mGlu5 receptor antagonist) protects hepatocytes against hypoxic damage and facilitates their metabolic recovery after re-oxygenation [1]. One way to interpret these results is that endogenous activation of mGlu5 receptors is translated into a death signal in cells that are made vulnerable by hypoxia. We have now extended the study to in vitro and in vivo models of oxidative stress, in which a perturbation of intracellular Ca<sup>2+</sup> homeostasis is recognized as a causative factor in liver cell damage. Here, we report that pharmacological blockade of mGlu5 receptors is highly protective against liver cell damage induced by either tert-butylhydroperoxide (t-BuOOH) in vitro [9]or acetaminophen in vivo [10–12].

#### 2. Materials and methods

Our studies involving animal experimentation were approved by the Italian Ministry of Health and by the University Commission for Animal Care following the criteria of the Italian National Research Council.

#### 2.1. Materials

2-Methyl-6-(phenylethynyl)-pyridine (MPEP), 6-methyl-2-(phenylazo)pyridin-3-ol (SIB-1757) and (E)-2-methyl-6-styryl-pyridine (SIB-1893) were purchased from Tocris Cookson Ltd. (Bristol, UK). All other drugs and chemicals were purchased from Sigma (Milan, Italy).

#### 2.2. Methods

## 2.2.1. Hepatocyte isolation, treatments and assessment of cell viability

Hepatocytes were isolated from male Wistar rats (200–250 g) by collagenase perfusion of the liver [13]. Cell viability, estimated at the beginning of the experiments, ranged between 85 and 90%. Cells were suspended in Krebs–Ringer–HEPES (KRH) buffer containing 115 mM NaCl, 5 mM KCl, 2 mM CaCl<sub>2</sub>, 1 mM KH<sub>2</sub>PO<sub>4</sub>, 1.2 mM MgSO<sub>4</sub> and 12.5 mM HEPES at pH 7.4, and all incubations were performed at a final cell density of 10<sup>6</sup> cells/ml in rotating round-bottomed flasks at 37 °C under 5% CO<sub>2</sub>/ 95% O<sub>2</sub> atmosphere. Hepatocytes were preincubated for 30 min with MPEP 30  $\mu$ M before exposure to the oxidant *tert*-butylhydroperoxide (t-BuOOH) (0.5 mM). Cell viability was assessed by measuring extracellular LDH activity [14].

# 2.2.2. Analysis of radical oxygen species and glutathione levels

Formation of radical oxygen species was monitored as follows. Hepatocytes were preloaded with the cell permeant probe dichlorodihydrofluorescein diacetate at concentrations of 5  $\mu$ M for 15 min prior to the addition of t-BOOH. At the indicated times, aliquots containing 10<sup>6</sup> cells were withdrawn and centrifuged at 2000 × g for 30 s. Cell pellets were resuspended in 0.5 ml distilled water and immediately frozen. Samples were quickly thawed and 200- $\mu$ l samples were transferred to a 96-well plate for fluorescence measurements. Fluorescence values were measured on a CytoFluor 4000 (excitation 485 nm, emission 530 nm).

The concentration of total glutathione was measured by the enzymatic recycling method described by Tieze et al. [15], using glutathione reductase and 5,5'-dithio-bis(2-nitrobenzoic acid). Glutathione disulphide (GSSG) was determined after derivatization of reduced glutathione (GSH) with 2-vinylpyridine. GSH levels were calculated from the difference between total glutathione (GSH + GSSG) and GSSG. Protein thiol levels were determined as described by Di Monte et al. and Griffith et al. [16,17]. Proteins were assayed according to the method of Lowry et al. [18]. Lipid-peroxidation was monitored by measuring the formation of malonyl-dialdehyde (MDA) as described by Gray [19].

#### 2.2.3. In vivo studies

Adult Swiss male mice (Charles River, 30–40 g), were injected intraperitoneally with acetaminophen (300 mg/kg), MPEP (20 mg/kg), SIB-1757 (20 mg/kg) or SIB-1893 (20 mg/kg) alone or in combination. All drugs were dissolved in saline containing 10% ethanol, which was injected in control mice (injection volume = 0.2 ml). In another set of experiments, acetaminophen was dissolved in heated saline brought to pH 8.5 with NaOH without ethanol. The solution containing acetaminophen and/or MPEP, SIB-1757 or SIB-1893 was injected at 37 °C to avoid the precipitation of acetaminophen. Some groups of mice were killed 24 h after a single injection. Additional groups of mice were treated with drugs daily for 6 days, and killed 25 days after the last administration. Animals were killed by decapitation and the liver was washed with saline perfusing the portal vein. The liver was then removed and frozen to -80 °C.

## 2.2.4. Measurement of N-acetylbenzoquinoneimine (NABQI) and GSH levels in liver

Animals treated with acetaminophen in the absence or presence of mGlu5 receptor antagonists were killed by decapitation 4 h after drugs injection. The liver was excised, rinsed in ice-cold 0.9% NaCl trimmed of adherent tissues, and weighed. An 11% liver homogenate (w/v) was prepared in 4.4% methaphosphoric acid (final concentration, 4%), using an all-glass homogenizer, and kept on ice. After standing for 20–40 min, the homogenate was centrifuged for 1 min (10000 × g) and the acid-soluble fraction was collected for measurement of NABQI. Analysis of NABQI was performed by HPLC with electrochemical detection essentially as described by Richie and Lang [20] with slight modifications. GSH levels in liver homogenates were determined as described above.

#### 2.2.5. Histochemical analysis

Serial unfixed cryostat sections were processed for the detection of glucose-6-phosphate dehydrogenase (G6PDH) activity and reactive oxygen species. For the detection of G6PDH activity, incubation media contained 10 mM glucose-6-phosphate (Sigma), 0.8 mM NADP (Sigma), 5 mM MgCl<sub>2</sub>, 0.44 mM mPMS, 5 mM sodium azide and 5 mM tetranitro blue tetrazolium chloride (TNBT; Sigma) [21]. For the detection of reactive oxygen species, incubation media contained 12.5 mM 3,3'-diaminobenzidine (DAB; Sigma), 2.5 mM MnCl<sub>2</sub>, and 40 mM CoCl<sub>2</sub> [22]. At the end of the incubation, sections were washed in hot distilled water (60 °C) to stop the reaction immediately and to remove the viscous incubation mediaum. Sections were then mounted in glycerol jelly and studied with a light microscopy. Conventional haematoxylin and eosin staining was used for the assessment of liver morphology.

## 2.2.6. Western blot analysis of inducible nitric oxide synthase (iNOS)

Livers from control or treated mice were removed, extensively washed in PBS (pH 7.4) and stored frozen at -80 °C. On the day of the experiment, livers were homogenized at 4 °C in ice-cold SDS-lysis buffer containing 1 mM PMSF, pH 7.4, with a motor-driven Teflon-glass homogenizer (1700 rev./min). Five microlitres were used for protein determinations. Seventy micrograms of proteins were resuspended in SDS-bromophenol blue redu

cing buffer with 20 mM DTT. Western blot analyses were carried out using 8% SDS polyacrylamide gels run on a minigel apparatus (BioRad, Mini Protean II Cell); gels were electroblotted on ImmunBlot PVDF Membrane (BioRad, Italy) for 1 h using a semi-dry electroblotting system (BioRad Trans-blot system SD), and filters were blocked overnight in TTBS buffer (100 mM Tris–HCl, 0.9% NaCl, 0.1% Tween-20, pH 7.4) containing 2% non-fat dry milk. Blots were then incubated for 1 h at room temperature with primary polyclonal antibodies (1  $\mu$ g/ml) which recognize a specific carboxy-terminal epitope of iNOS (Transduction Laboratories, Lexington, KY). Blots were washed three times with TTBS buffer and then incubated for 1 h with secondary antibodies (peroxidase-coupled anti-mouse, Amersham) diluted 1:3000 with TTBS. Immunostaining was revealed by ECL (Amersham).

#### 2.2.7. Measurement of iNOS activity in liver homogenates

Activity of iNOS was assessed by measuring the conversion of [L-14C]arginine into [L-14C]citrulline in liver homogenates incubated in the absence of calcium [23]. Frozen tissues were pulverized and placed in 5 volumes of ice-cold homogenization buffer (25 mM Tris-HCl (pH 7.4), 1 mM EDTA, 1 mM EGTA). An aliquot of total homogenates was used for protein determination. The reaction was carried out in triplicate; non specific activity was determined in the presence of 1 mM L-NAME. The reaction was started by adding 50 µl of protein homogenates to 50 µl of 50 mM Tris-HCl (pH 7.4), containing 0.3 µM tetrahydrobiopterin, 1 µM flavin adenine dinucleotide, 1 µM flavin adenine mononucleotide, 0.1 µM calmodulin, 1 µM NADPH, 0.5 µCi [<sup>14</sup>C]arginine (specific activity at 359 mCi/mmol, Amersham), 1 mM EGTA with or without 2 mM L-NAME. The reaction was carried out at 27 °C for 1 h and terminated by adding 400 µl of ice-cold stop buffer (20 mM HEPES, 5 mM EDTA, pH 5.5). Separation of [L-<sup>14</sup>C]arginine from [L-<sup>14</sup>C]citrulline was accomplished by using affinity columns containing a resin that retains the charged species of [L-<sup>14</sup>C]argi-C]arginine while allowing [L-<sup>14</sup>C]citrulline to pass through. Thus the assay mixture was passed over Poly-Prep Chromatography columns (BioRad) loaded with 1 ml of equilibrated Dowex 50W-X8 Na<sup>+</sup> form 200 mesh molecular biology grade resin (Sigma Aldrich), and the eluate was collected. The column was washed with 4 ml of water during collection of the eluate. An aliquot of each eluate was added to 5 ml of scintillation fluid, and [L-14C]citrulline activity was determined using a Beckman LS6500 liquid scintillation counter. Blank incubation contained 50 µl of protein-free homogenization buffer. NO production by iNOS was calculated as picomoles of [L-<sup>14</sup>C]citrulline produced per milligram of protein per hour.

### 3. Results

### 3.1. mGlu5 receptor antagonists protect isolated hepatocytes against oxidative damage produced by t-BuOOH

Addition of t-BuOOH (0.5 mM) to isolated hepatocytes induced a time-dependent cell death, with about 70% of hepatocytes being damaged after 3.5 h of exposure. Cell damage was substantially delayed when hepatocytes were treated with 30  $\mu$ M of either MPEP or SIB-1893 [24,25] (both applied 30 min prior to t-BuOOH) (Fig. 1A). These concentrations of MPEP and SIB-1893 are proven to be maximally protective against neuronal death in culture [26]. In another experiment, hepatocytes were exposed to t-BuOOH after pretreatment with different concentrations of MPEP. MPEP was protective at concentrations as low as 30 nM (Fig. 2A,B), which coincide with the IC<sub>50</sub> value reported for the inhibition of recombinantly expressed mGlu5 recep-



Fig. 1. Protective effect of MPEP and SIB-1893 against tBuOOHinduced cell damage in isolated hepatocytes. Closed circles, untreated hepatocytes; open circles, hepatocytes exposed to t-BuOOH (0.5 mM); closed triangles: hepatocytes pretreated for 30 min with MPEP (30  $\mu$ M) and then exposed to t-BuOOH; open triangles, hepatocytes exposed to MPEP; closed squares, hepatocytes pretreated for 30 min with SIB-1893 (30  $\mu$ M) and then exposed to t-BuOOH; open squares, hepatocytes exposed to SIB-1893. Results are mean ± SEM of 4–8 individual determinations. \**P* < 0.05 (One-way ANOVA + Fisher PLSD) vs. t-BuOOH alone.

tors [24]. Neither MPEP nor SIB-1893 affected hepatocyte viability per se (Fig. 1). Both MPEP and SIB-1893 reduced the formation of radical oxygen species in hepatocytes treated with t-BuOOH, as shown by the use of the fluorescent probe, dichlorofluorescein diacetate (Table 1, only MPEP), by measurements of MDA (a final product of lipid peroxidation) (Fig. 3A), and by the detection of the free thiol groups of proteins (Fig. 3B). However, neither MPEP nor SIB-1893 prevented the reduction in intracellular GSH levels induced by t-BuOOH (Fig. 3C). MPEP induced per se a small reduction in intracellular GSH levels, which was

Table 1

Reactive oxygen species formation in cultured hepatocytes treated with t-BOOH in the absence or presence of MPEP<sup>a</sup>

Time (min)	% of the initial fluorescence t-BOOH	t-BOOH + MPEP
0	$92 \pm 4.9$	$87 \pm 2$
30	$122 \pm 7.7$	$84 \pm 4.1*$
60	$136 \pm 7.8$	$84 \pm 2.5*$
90	$141 \pm 8.6$	$86 \pm 5.7*$
120	$160 \pm 14$	$92 \pm 13^{*}$
150	$172 \pm 16$	$104 \pm 17^*$

<sup>a</sup> Values (referred to as the fluorescence generated by dichlorofluorescein diacetate) were calculated from four or five individual determinations. \*P < 0.05 (Student's *t*-test), vs. values obtained with t-BOOH alone. MPEP alone did not affect fluorescence in hepatocytes which were not treated with t-BOOH (not shown).



Fig. 2. Concentration dependent protection by MPEP against hepatocyte toxicity induced by t-BuOOH. In (A), different concentrations of MPEP were added to isolated hepatocytes 30 min prior to the addition of 0.5 mM t-BuOOH. Values are means  $\pm$  SEM of 4 determinations. All points with t-BuOOH + MPEP in a concentration range between 30 nM and 3  $\mu$ M were significantly different from the respective values with t-BuOOH alone at time points from 60 to 180 min. Values obtained with t-BuOOH + 3 nM MPEP were significantly different from t-BuOOH alone at 60 and 90 min (P < 0.05, one-way ANOVA + Fisher PLSD). The concentration-dependent protection by MPEP after 180 min of exposure to t-BuOOH is shown in (B). In this particular case, values are expressed as per cent of t-BuOOH toxicity and were calculated from the means shown in (A). Note that MPEP is maximally effective at 300 nM. At concentrations of 300  $\mu$ M, MPEP completely lost its cytoprotective activity against t-BuOOH toxicity.

additive to the larger reduction induced by t-BuOOH (Fig. 3C). We also combined t-BuOOH with either glutamate or quisqualate (both at 100  $\mu$ M), which are known to activate mGlu5 receptors. Measurements of cell viability showed that neither of these drugs potentiated the toxic effect of t-BuOOH (not shown). However, this was expected because isolated hepatocytes release micromolar amounts of glutamate that are sufficient to saturate mGlu5 receptors [1].



Fig. 3. Same as Fig. 1, but showing MDA formation (A), thiol groups of proteins (B) and GSH levels (C). Results are mean  $\pm$  SEM of 4–6 individual determinations. \*P < 0.05 (one-way ANOVA + Fisher PLSD) vs. t-BuOOH alone.

## 3.2. mGlu5 receptor antagonists are protective against liver damage induced by acetaminophen in mice

In a first series of experiments, mice were treated intraperitoneally only once with acetaminophen (300 mg/kg) and examined 24 h later. Acetaminophen treatment induced centrilobular liver necrosis, as shown by Fig. 4A. There was no difference in acetaminophen-induced toxicity as well as in the effect of mGlu5 receptor antagonists (see below) between mice injected with a solution containing 10% ethanol and those injected with an ethanol-free solution at pH 8.5. Co-injection with MPEP (20 mg/kg, i.p.) protected against acetaminophen toxicity (Fig. 4B). MPEP treatments also reduced the formation of reactive oxygen species (Fig.5A–C) and the increase in G6PDH activity (Fig. 6A–C) induced by acetaminophen, although it did not prevent the reduction in liver GSH levels induced by acetaminophen (Table 2). Animals killed 24 h after a single injection of acetaminophen were also used for the detection of iNOS expression and activity in the liver homogenates. Western blot analysis with an anti-iNOS antibody showed the presence of a single band of 130 kDa, which corresponds to the deduced molecular size of iNOS [23]. A single injection with acetaminophen greatly enhanced iNOS expression in the liver. This increase was markedly reduced in mice coinjected with MPEP. MPEP alone had no effect on iNOS expression (Fig. 7A). Similar results were obtained by measuring iNOS activity as the amount of [<sup>14</sup>C]citrulline formed from [<sup>14</sup>C]arginine in liver homogenates incubated in the absence of calcium. Acetaminophen treatment increased iNOS activity by more than 3-fold. This increase was largely reduced when acetaminophen was co-injected with MPEP, SIB-1893, or SIB-1757 (all at 20 mg/kg, i.p.) (Fig. 7B). Additional groups of mice were treated intraperitoneally for 6 days with 300 mg/kg of acetaminophen given alone or in combination with MPEP (20 mg/kg), and killed



Fig. 4. Haematoxylin–eosin staining in liver sections of mice treated as follows: (A) 24 h after a single injection of acetaminophen (300 mg/kg, i.p.); (B) 24 h after a single injection of acetaminophen + MPEP (20 mg/kg, i.p.); (C) 25 days after a 6-day treatment with acetaminophen (300 mg/kg, i.p., once per day); (D) 25 days after a 6-day treatment with acetaminophen + MPEP (20 mg/kg, i.p., once per day). Arrowheads in (A) and (C) point to areas of centrilobular necrosis. Objective =  $40 \times .$ 



Fig. 5. Histochemical detection of reactive oxygen species in liver sections of mice that received a single injection of: (A) saline; (B) acetaminophen (300 mg/kg, i.p.); and (C) acetaminophen + MPEP (20 mg/kg, i.p.).

25 days after the end of the treatment. Mice treated with acetaminophen alone showed extensive liver necrosis (Fig. 4C) at the time of the sacrifice. Mice co-injected with MPEP were largely protected against acetaminophen toxicity (Fig. 4D). MPEP also prevented the increase in reactive oxygen species and G6PDH activity induced by acetaminophen treatment, as detected by histochemical analysis (not



Fig. 6. Histochemical detection of glucose-6-phosphate dehydrogenase (G6PDH) activity in liver sections of mice that received a single injection of: (A) saline; (B) acetaminophen (300 mg/kg, i.p.); and (C) acetaminophen + MPEP (20 mg/kg, i.p.).

shown). We examine whether mGlu5 receptor antagonists could affect the hepatic conversion of acetaminophen into the reactive metabolite, NABQI. NABQI levels, detected by HPLC, were about 100 ng/g of liver 4 h after a single injection of acetaminophen in mice. These levels did not change in mice co-injected with either MPEP or SIB-1893 (Table 3).

 Table 2

 Liver GSH levels mice receiving a single injection of acetaminophen in the absence or presence of MPEP<sup>a</sup>

	GSH levels (nmol/mg protein)
Saline	$36 \pm 2.5$
MPEP	$32 \pm 1.5$
Acetaminophen	$22 \pm 0.8^{*}$
Acetaminophen + MPEP	$21 \pm 1.8^{*}$

<sup>a</sup> Values are means  $\pm$  SEM of four individual determinations. \**P* < 0.05 (One-way ANOVA + Fisher PLSD) vs. the corresponding values obtained in the absence of acetaminophen.



Fig. 7. (A) Western blot analysis of iNOS in protein extracts prepared from the livers of mice treated with a single injection of saline, acetaminophen (300 mg/kg, i.p.), MPEP (20 mg/kg, i.p.), or acetaminophen + MPEP. The band corresponding to iNOS is visible at 130 kDa. (B) iNOS activity in liver homogenates from mice treated with a single injection of saline, acetaminophen (300 mg/kg, i.p.), MPEP (20 mg/kg, i.p.), SIB-1893 (20 mg/kg, i.p.), SIB-1757 (20 mg/ kg, i.p.), acetaminophen + MPEP, acetaminophen + SIB-1893, or acetaminophen + SIB-1757. Ctrl = controls, i.e. mice which did not receive any mGlu5 receptor antagonist. Values (means  $\pm$  SEM) are expressed as % of values obtained in mice treated with acetaminophen alone, and were calculated from 4-8 individual determinations. \*P < 0.01 (one-way ANOVA + Fisher PLSD) vs. acetaminophen alone. In mice injected with saline and acetaminophen alone, iNOS activity was  $330 \pm 25$  and  $1045 \pm 96$  pmol of [<sup>14</sup>C]citrulline formed from [<sup>14</sup>C]arginine/mg protein per hour, respectively.

Table 3

Detection of NABQI in the liver of	f mice receiving a single injection of
acetaminophen in the absence or J	presence of MPEP or SIB-1893 <sup>a</sup>

	NABQI (ng/g tissue)
Acetaminophen	$91 \pm 31$
Acetaminophen + MPEP	$102 \pm 26$
Acetaminophen + SIB-1893	$128 \pm 42$

 $^{\rm a}\,$  Values are means  $\pm$  SEM of four individual determinations.

#### 4. Discussion

We have used the antagonists MPEP, SIB-1757 and SIB-1893 [24,25]to examine how endogenous activation of mGlu5 receptors contributes to oxidative liver damage. These drugs behave as non-competitive antagonists, interacting with a binding pocket lined by the transmembrane domains 3, 6 and 7 [27]. Thus, the effects of these drugs cannot be overwhelmed by the endogenous glutamate. In isolated hepatocytes, MPEP is protective against hypoxic damage and facilitates cell recovery after re-oxygenation [1]. Hence, we have hypothesized that endogenous activation of mGlu5 receptors becomes detrimental in cells that are made vulnerable by a specific insult. mGlu5 receptors are coupled to polyphosphoinositide hydrolysis [7,28,29,30], and their activation generates oscillatory increases in intracellular Ca<sup>2+</sup> [31]. An increase in intracellular Ca<sup>2+</sup> is involved in liver cell damage induced by oxidative stress[32]. For example, hepatic cell death induced by t-BuOOH follows a perturbation in intracellular Ca<sup>2+</sup> homeostasis, which is a direct consequence of t-BuOOH metabolism by the glutathione peroxidaseglutathione reductase system [33,34]. Hence, we have hypothesized that activation of mGlu5 receptors by the endogenous glutamate could act synergistically with oxidizing agents in the induction of liver cell damage. This was supported by the protective effect of MPEP and SIB-1893 against t-BuOOH toxicity in isolated hepatocytes, although the time-dependent profile shown in Fig. 1A suggests that mGlu5 receptor blockade delays rather than preventing cell death. Interestingly, MPEP and SIB-1893 reduced ROS formation without increasing the intracellular levels of GSH. Addition of MPEP even reduced GSH levels, and this may help explain why the drug was less efficient than SIB-1893 in the MDA assay. Our data suggest that mGlu5 receptor antagonists do not interfere with the GSH-mediated t-BuOOH metabolism and that cell protection cannot be entirely ascribed to a reduced ROS formation. We therefore hypothesize that endogenous activation of mGlu5 receptors is permissive to the induction of cell death in hepatocytes challenged with t-BuOOH, although the possibility that MPEP and SIB-1893 act as intracellular free radical scavengers cannot be entirely ruled out. To examine whether a similar scenario occurs in vivo, we have treated mice with toxic doses of acetaminophen combined with mGlu5 receptor antagonists. The doses of MPEP that we have used were

shown to be active in models of neurological disorders [35,36]. Acetaminophen (300 mg/kg, i.p.) induced an extensive centrilobular liver necrosis that was substantial 24 h after a single injection. This effect is due to the bioactivation of acetaminophen by cytochrome P-450 leading to the formation of NABQI, a highly reactive metabolite that forms chemical adducts with proteins after intracellular GSH is depleted [10]. Induction of iNOS, with ensuing formation of NO<sup>-</sup> and nitration of protein tyrosines also contributes to the development of acetaminophen toxicity [37]. In control mice, acetaminophen induced a substantial increase in ROS formation and in the expression and activity of iNOS. All these effects were reduced when acetaminophen was combined with mGlu5 receptor antagonists. The protective activity of MPEP in vivo was confirmed in a more drastic model of liver toxicity, in which acetaminophen was administered for 6 days. The lack of changes in tissue levels of NABQI in response to MPEP or SIB-1893 suggests that endogenous activation of liver mGlu5 does not affect acetaminophen metabolism but rather enables the engagement of the death pathway in response to acetaminophen. Whether or not mGlu5 receptor antagonists can be used for prophylaxis or treatment of liver toxicity induced cannot be predicted at this time because information on the safety profile of these drugs are still lacking. The possibility that a long-term treatment with MPEP or the SIBs generates some toxic phenylpyridine metabolites raises some major concerns for the use of these drugs, although mice treated with MPEP or the SIBs showed neither signs of liver toxicity nor remarkable changes in spontaneous behaviour. Nonetheless, the possibility that mGlu5 receptors are targeted by novel drugs endowed with protective activity against liver toxicity is certainly exciting and worth to be investigated.

### Acknowledgements

The authors are grateful to Gaetano Viani, Fabrizio Rossi, Barbara Riozzi and Fabrizio Pontarelli for their continuous technical support in the preparation of the manuscript.

### References

- Storto M, de Grazia U, Knöpfel T, Canonico PL, Copani A, Richelmi P, et al. Selective blockade of mGlu5 metabotropic glutamate receptors protects rat hepatocytes against hypoxic damage. Hepatology 2000;3:649–655.
- [2] Moroni F, Luzzi S, Franchi-Micheli S, Ziletti L. The presence of Nmethyl-D-aspartate-type receptors for glutamic acid in the guinea pig myenteric plexus. Neurosci Lett 1986;68:57–62.
- [3] Inagaki N, Kuromi H, Gonoi T, Okamoto Y, Ishida H, Seino Y, et al. Expression and role of ionotropic glutamate receptors in pancreatic islet cells. FASEB J 1995;9:686–691.
- [4] Chaudhari N, Yang H, Lamp C, Delay E, Cartford C, Than T, Roper S. The taste of monosodium glutamate: membrane receptors in taste buds. J Neurosci 1996;16:3817–3826.
- [5] Gu Y, Publicover J. Expression of functional metabotropic glutamate

receptors in primary cultured rat osteoblast. J Biol Chem 2000;275:34252–34259.

- [6] Pin J-P, Duvoisin R. The metabotropic glutamate receptors: structure and functions. Neuropharmacology 1995;34:1–26.
- [7] Sureda F, Copani A, Bruno V, Knöpfel T, Meltzger G, Nicoletti F. Metabotropic glutamate receptor agonists stimulate polyphosphoinositide hydrolysis in primary cultures of rat hepatocytes. Eur J Neurosci 1997;338:R1–R2.
- [8] Nicoletti F, Bruno V, Copani A, Casabona G, Knopfel T. Metabotropic glutamate receptors: a new target for the therapy of neurodegenerative disorder. Trends Neurosci 1996;19:267–271.
- [9] Bellomo G, Martino A, Richelmi P, Moore AG, Jewell SA, Orrenius S. Pyridine-nucleotide oxidation. Ca<sup>2+</sup> cycling and membrane damage during tert-butyl hydroperoxide metabolism by rat liver mitochondria. Eur J Biochem 1984;40:1–6.
- [10] Hinson JA, Pohl LR, Monks TJ, Gillette JR. Acetaminophen-induced hepatotoxicity. Life Sci 1981;29:107.
- [11] Michael LS, Pumford NR, Mayeux PR, Niesman MR, Hinson JA. Pretreatment of mice with macrophage inactivators decrease acetaminophen hepatotoxicity and the formation of reactive oxygen and nitrogen species. Hepatology 1999;30:186–195.
- [12] Van de Straat R, De Vries J, Debets AJJ, Vermeulen NPE. The mechanism of prevention of paracetamol induced hepatotoxicity by 3,5-dialkyl substitution. Biochem Pharmacol 1987;13:2065–2070.
- [13] Moldeus P, Hogberg J, Orrenius S. Isolation and use of liver cells. Methods Enzymol 1978;51:60–70.
- [14] Bergmeyer HU. Methods of enzymatic analysis, New York: Academic Press, 1965. pp. 736–743.
- [15] Tieze F. Enzymatic method for quantitative determination of nanogram amounts of total and oxidized glutathione: applications to mammalian blood and other tissue. Anal Biochem 1969;27:502–522.
- [16] Di Monte D, Ross D, Bellomo G, Eklow L, Orrenius S. Alterations in intracellular thiol homeostasis during the metabolism of menadione by isolated rat hepatocytes. Arch Biochem Biophys 1984;235:334–342.
- [17] Griffith OW. Determination of glutathione and glutathione disulfide using reductase and 2-vinylpyridine. Anal Biochem 1980;106:207– 212.
- [18] Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem 1951;193:265–275.
- [19] Gray JI. Measurement of lipid oxidation. J Am Oil Chem Soc 1978;43:539–546.
- [20] Richie JP, Lang CA. The determination of glutathione, cysteine and other thiols and disulfides in biological samples using high-performance liquid chromatography with dual electrochemical detection. Anal Biochem 1987;163:9–15.
- [21] Van Noorden CJF. Histochemistry and cytochemistry of glucose-6phosphate dehydrogenase. Prog Histochem Cytochem 1984;15/4:1– 85.
- [22] Kerver ED, Vogels IMC, Bosch KS, Vreeling-Sindelárová H, Van den Munckhof RJM, Frederiks WM. In situ detection of spontaneous superoxide anion and singlet oxygen production by mitochondria in rat liver and small intestine. Histochem J 1997;29:229–237.
- [23] Gardner RC, Heck DE, Yang CS, Thomas PE, Zhang XJ, DeGeorge GL, et al. Role of nitric oxide in acetaminophen induced hepatotoxicity in the rat. Hepatology 1998;3:748–754.
- [24] Gasparini F, Lingenhoehl K, Stoehr N, Flor PJ, Heinrich M, Vranesic I, et al. 2-Methyl-6-(phenylethynyl)-pyridine (MPEP), a potent, selective and systemically active mGlu5 receptor antagonist. Neuropharmacology 1999;38:1493–1503.
- [25] Varney MA, Cosford ND, Jachec C, Rao SP, Sacaan A, Lin FF, et al. SIB-1757 and SIB-1893: selective, noncompetitive antagonists of metabotropic glutamate receptor type 5. J Pharmacol Exp Ther 1999;290(1):170–181.
- [26] Bruno A, Ksiazek I, Battaglia G, Lukic S, Leonhardt T, Sauer D, et al. Selective blockade of metabotropic glutamate receptor subtype 5 is neuroprotective. Neuropharmacology 2000;39:2223–2230.

- [27] Pagano A, Ruegg D, Litshig S, Stoehr N, Stierlin C, Heinrich M, et al. The non-competitive antagonists 2-methyl-6-(phenylethynyl)pyridine and 7-hydroxyiminocyclopropan[b]chromen-1a-carboxylic acid ethyl ester interact with overlapping binding pockets in the transmembrane region of group I metabotropic glutamate receptors. J Biol Chem 2000;275:33750–33758.
- [28] Abe T, Sugihara H, Nawa H, Shigemoto R, Nakanishi S. Molecular characterization of a novel metabotropic glutamate receptor mGluR5 coupled to inositol phosphate/Ca<sup>2+</sup> signal transduction. J Biol Chem 1992;267:13361–13365.
- [29] Casabona G, Knöpfel T, Kuhn R, Gasparini F, Baumann P, Sortino MA, et al. Expression and coupling to polyphosphoinositide hydrolysis of group I metabotropic glutamate receptors in early postnatal and adult rat brain. Eur J Neurosci 1997;9:12–17.
- [30] Miller S, Romano C, Cotman CW. Growth factor upregulation of a phosphoinositide-coupled metabotropic glutamate receptor in cortical astrocytes. J Neurosci 1995;15:6103–6109.
- [31] Kawabata S, Tsutsumi R, Kohara A, Yamaguchi T, Nakanishi S, Okada M. Control of calcium oscillations by phosphorylation of metabotropic glutamate receptors. Nature 1996;383:89–92.
- [32] Jewell SA, Bellomo G, Thor H, Orrenius S, Smith MT. Bleb formation in hepatocytes during drug metabolism is caused by distur-

bances in thiol and calcium ion homeostasis. Science 1982;217: 1257-1259.

- [33] Bellomo G, Jewell SA, Thor H, Orrenius S. Regulation of intracellular calcium compartmentation: studies with isolated hepatocytes and tbutyl hydroperoxide. Proc Natl Acad Sci USA 1982;79:6842–6846.
- [34] Bellomo G, Martino A, Richelmi P, Moore GA, Jewell SA, Orrenius S. Pyridine-nucleotide oxidation. Ca<sup>2+</sup> cycling and membrane damage during tert-butyl hydroperoxide metabolism by rat-liver mitochondria. Eur J Biochem 1984;140:1–6.
- [35] Meldrum SB, Williams M, Nanan K, Chapman AG. Anticonvulsant activity of two metabotropic glutamate group I antagonists selective for the mGlu5 receptor: 2-methyl-6-(phenylethynyl)-pyridine (MPEP) and (E)-6-methyl-2-styryl-pyridine (SIB1893). Neuropharmacology 2000;9:1567–1574.
- [36] Walker K, Reeve A, Bowes M, Winter J, Wotherspoon G, Davis A, et al. mGlu5 receptors and nociceptive function II. mGlu5 receptors functionally expressed on peripheral sensory neurones mediate inflammatory hyperalgesia. Neuropharmacology 2001;40(1):10–19.
- [37] Michael SL, Pumford NR, Mayeux PR, Niesman MR, Hinson JA. Pretreatment of mice with macrophage inactivators decreases acetaminophen hepatotoxicity and the formation of reactive oxygen and nitrogen species. Hepatology 1999;30:186–195.